Eslicarbazepine acetate（神経因性疼痛）：医薬品市場予測及び分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 12
3.1 Clinical Manifestations of Neuropathic Pain – Signs and Symptoms 14
3.1.1 Painful Diabetic Neuropathy 16
3.1.2 Postherpetic Neuralgia 17
3.1.3 Trigeminal Neuralgia 17
3.2 Etiology and Pathophysiology 18
3.2.1 Etiology 19
3.2.2 Pathophysiology 20
4 Disease Management 28
4.1 Diagnosis and Treatment Overview 28
4.1.1 Diagnosis 28
4.1.2 Treatment Overview and Guidelines 35
5 Competitive Assessment 45
5.1 Overview 45
6 Unmet Need and Opportunity 50
6.1 Overview 50
6.2 Physician Knowledge or Awareness 51
6.2.1 Unmet Need 51
6.2.2 Gap Analysis 52
6.2.3 Opportunity 53
6.3 Diagnostic Challenges 53
6.3.1 Unmet Need 53
6.3.2 Gap Analysis 54
6.3.3 Opportunity 54
6.4 Low Treatment Rate and Underdosing of Medications 54
6.4.1 Unmet Need 54
6.4.2 Gap Analysis 56
6.4.3 Opportunity 56
6.5 Unsatisfactory Efficacy and Safety Profiles of Pharmacological Treatments 57
6.5.1 Unmet Need 57
6.5.2 Gap Analysis 58
6.5.3 Opportunity 58
6.6 Elderly Patient Population – Drug Tolerability 59
6.6.1 Unmet Need 59
6.6.2 Gap Analysis 59
6.6.3 Opportunity 60
6.7 Rational or Personalized Therapies 60
6.7.1 Unmet Need 60
6.7.2 Gap Analysis 61
6.7.3 Opportunity 61
7 Pipeline Assessment 63
7.1 Overview 63
7.2 Promising Drugs in Clinical Development 64
8 Eslicarbazepine Acetate 67
8.1 Overview 67
8.2 Efficacy 68
8.3 Safety 69
8.4 Dosing and Formulation 70
8.5 Potential Clinical and Commercial Positioning 70
8.6 Pricing and Reimbursement 70
8.7 SWOT Analysis 71
8.8 Forecast 71
9 Appendix 73
9.1 Bibliography 73
9.2 Abbreviations 77
9.3 Methodology 80
9.4 Forecasting Methodology 80
9.4.1 Diagnosed PDN, PHN, and TN Patients 81
9.4.2 Percent Drug-Treated Patients 81
9.4.3 General Pricing Assumptions 81
9.4.4 Generic Erosion 82
9.4.5 Pricing of Pipeline Agents 82
9.5 Physicians and Specialists Included in This Study 82
9.6 About the Authors 84
9.6.1 Author 84
9.6.2 Global Head of Healthcare 85
9.7 About GlobalData 86
9.8 Disclaimer 86